KEAP1 and non-small cell lung carcinoma: Whereas EZH inhibits NFE2L2 expression and decreases NSCLC growth in vivo and in vitro [125], hypermethylation of KEAP1 promoter inhibits its expression and results in increased NRF2 levels [164].